VARIABLES | Demographics (264 = 100%) | Latissimus Dorsi (18 = 6.8%) | TRAM Flap (84 = 31.8%) | Tissue Expander (138 = 52.2%) | Direct-to-implant (24 = 9.09%) |
Type of breast cancer |
|
|
|
|
|
Invasive ductal carcinoma (n/%) | 228 (86.3%) | 18 (100%) | 6 (7.14%) | 6 (4.5%) | 6 (20%) |
Ductal carcinoma in situ (n/%) | 16 (6.06%) | 0 | 66 (78.57%) | 126 (95.5%) | 10 (33.3%) |
Invasive lobular carcinoma (n/%) | 14 (5.03%) | 0 | 6 (7.14%) | 0 | 8 (26.66%) |
Lobular carcinoma in situ (n/%) | 6 (2.2%) | 0 | 6 (7.14%) | 0 | 6 (20%) |
Receptor |
|
|
|
|
|
Estrogen receptor positive (n/%) | 186 (70.45%) | 12 (66.6%) | 54 (64.2%) | 102 (77.2%) | 12 (50%) |
Estrogen receptor negative (n/%) | 78 (29.55%) | 6 (33.4%) | 30 (35.8%) | 30 (22.8%) | 12 (50%) |
Progesterone receptors positive (n/%) | 162 (61.3%) | 6 (33.3%) | 54 (64.2%) | 96 (72.7%) | 6 (25%) |
Progesterone receptors negative (n/%) | 102 (38.6%) | 12 (66.6%) | 30 (35.7%) | 42 (27.3%) | 18 (75%) |
HER2-positive (n/%) | 144 (54.5%) | 6 (33.3%) | 36 (42.8%) | 96 (72.7%) | 6 (25%) |
HER2-negative (n/%) | 120 (45.4%) | 12 (66.6%) | 48 (57.1%) | 42 (27.3%) | 18 (75%) |
Laterality |
|
|
|
|
|
Right (n/%) | 138 (52.2%) | 12 (66.6%) | 0 | 66 (50%) | 18 (75%) |
Left (n/%) | 108 (40.9%) | 6 (33.3%) | 42 (50%) | 54 (40.9%) | 6 (25%) |
Bilateral (n/%) | 18 (6.8%) | 0 | 42 (50%) | 12 (9.09%) | 0 |